A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel

Saeed, Kordo, Ahmad-Saeed, Nusreen, Annett, Rachel, Barlow, Gavin, Barrett, Lucinda, Boyd, Sara E., Boran, Nicola, Davies, Peter, Hughes, Harriet, Jones, Gwennan, Leach, Laura, Lynch, Maureen, Nayar, Deepa, Maloney, Robert J., Marsh, Martin, Milburn, Olivia, Mitchell, Shanine, Moffat, Lynn, Moore, Luke S. P., Murphy, Michael E., O'Shea, Shaan Ashk, O'Sullivan, Fionnuala, Peach, Teresa, Petridou, Christina, Reidy, Niamh, Selvaratnam, Mathyruban, Talbot, Ben, Taylor, Vanessa, Wearmouth, Deborah and Aldridge, Catherine 2023. A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel. European Journal of Clinical Microbiology and Infectious Diseases 42 (2) , 169–176. 10.1007/s10096-022-04538-w

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (850kB) | Preview

Abstract

Septic arthritis is a serious condition with significant morbidity and mortality, routinely diagnosed using culture. The FDA has recently approved the rapid molecular BioFire® Joint Infection Panel (BJIP) for synovial fluid. We aimed to evaluate the BJIP compared to culture and its potential use in patient management. A multicentre retrospective evaluation of BJIP was conducted in the UK and Ireland. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated between the BJIP and routine culture. A multidisciplinary team (MDT) discussion addressing the optimal or potential case use of the assay practice was facilitated. Three hundred ninety-nine surplus synovial fluid samples (~ 70% from native joints) from eight centres were processed using BJIP in addition to routine culture. An increased yield of positive results was detected using BJIP compared to routine culture (98 vs 83), giving an overall PPA of 91.6% and overall NPA of 93% for the BJIP compared to culture results. The BJIP detected resistant markers and additional organisms that could influence antibiotic choices including Neisseria gonorrhoeae and Kingella kingae. The MDT agreed that the assay could be used, in addition to standard methods, in adult and children patients with specialist advice use based on local needs. Rapid results from BJIP were assessed as having potential clinical impact on patient management. Organisms not included in the panel may be clinically significant and may limit the value of this test for PJI.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Springer
ISSN:	0934-9723
Date of First Compliant Deposit:	10 February 2023
Date of Acceptance:	28 November 2022
Last Modified:	03 May 2023 07:42
URI:	https://orca.cardiff.ac.uk/id/eprint/156884

Actions (repository staff only)

Edit Item